Get the Stockscreener App
3.73
6.98%
-0.28
After Hours:
3.74
0.01
+0.27%
Design Therapeutics Inc stock is traded at $3.73, with a volume of 69,291.
It is down -6.98% in the last 24 hours and down -15.03% over the past month.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
See More
Previous Close:
$4.01
Open:
$3.96
24h Volume:
69,291
Relative Volume:
0.52
Market Cap:
$211.75M
Revenue:
-
Net Income/Loss:
$-66.86M
P/E Ratio:
-3.1083
EPS:
-1.2
Net Cash Flow:
$-58.82M
1W Performance:
-2.10%
1M Performance:
-15.03%
6M Performance:
-37.83%
1Y Performance:
-5.33%
1-Day Range:
$3.665
$3.96
1-Week Range:
$3.665
$4.125
52-Week Range:
$2.60
$7.77
Design Therapeutics Inc Stock (DSGN) Company Profile
Name
Design Therapeutics Inc
Sector
Industry
Phone
858-293-4900
Address
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
3.73 | 216.29M | 0 | -66.86M | -58.82M | -1.20 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-14-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-15-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-15-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Aug-15-23 | Downgrade | Wedbush | Outperform → Neutral |
| May-04-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-10-22 | Initiated | Wedbush | Outperform |
| May-02-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-19-22 | Initiated | Goldman | Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-20-21 | Initiated | Piper Sandler | Overweight |
| Apr-20-21 | Initiated | SVB Leerink | Outperform |
View All
Design Therapeutics Inc Stock (DSGN) Latest News
40,289 Shares in Design Therapeutics, Inc. (NASDAQ:DSGN) Acquired by BNP Paribas Financial Markets - Defense World
Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference - The Globe and Mail
Myotonic Dystrophy Market to Expand Significantly by 2034, - openPR.com
As Gold Pushes Higher, Junior Miners Begin to Show Signs of Life - The Globe and Mail
Palantir vs. IBM: The Breakthrough Wall Street Is Missing - The Globe and Mail
Is Pfizer Stock a Buy After This $1.25 Billion Investment? - The Globe and Mail
Northern Trust Corp Purchases 51,351 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
3 Penny Stocks With Market Caps As Low As $70M To Watch - Yahoo Finance
Scratch That? De Novo Antibody Design Enters the AI Drug Discovery Toolbox - Genetic Engineering and Biotechnology News
Promontory Therapeutics Announces Successful End of Phase 2 Meeting with US FDA on Phase 3 Registrational Study Design for PT-112 in Patients with Metastatic Castration-Resistant Prostate Cancer - PR Newswire
Design Therapeutics, Inc. (NASDAQ:DSGN) Stock Holdings Increased by Dimensional Fund Advisors LP - Defense World
Leerink Partnrs Analysts Lower Earnings Estimates for DSGN - The AM Reporter
Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference - The Manila Times
Quantum Sandbox Act: Why These 3 Quantum Stocks Could Be Ready to Explode - The Globe and Mail
Q2 EPS Forecast for Design Therapeutics Reduced by Analyst - Defense World
Chardan Capital Issues Optimistic Forecast for CRSP Earnings - Defense World
FY2025 EPS Estimates for EYPT Decreased by Cantor Fitzgerald - Defense World
Wells Fargo & Company MN Boosts Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
FY2025 Earnings Forecast for GPCR Issued By Leerink Partnrs - Defense World
Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer - The Globe and Mail
Ataxia Pipeline: Advancing Therapeutics and 32+ Leading - openPR.com
Barclays PLC Has $639,000 Stock Position in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Peptone Establishes Strategic Partnership with Evotec to Selectively Target Intrinsically Disordered Proteins (IDPs) and Advance Small-Molecule Therapeutics at Scale - Morningstar
Design Therapeutics Inc Files For Mixed Shelf Of Up To $300 MillionSEC Filing - marketscreener.com
Design Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results - The Manila Times
Design Therapeutics, Inc. SEC 10-Q Report - TradingView
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter ... - Bluefield Daily Telegraph
Invesco Ltd. Buys New Stake in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
AI Proteins to Present Key Advances in Miniprotein Therapeutics Development at PEGS Boston 2025 - Business Wire
Friedreich's Ataxia Market Growth | Trends, Treatments & - openPR.com
Design Therapeutics reports positive outcomes from trial of DT-168 eye drops - Yahoo Finance
Design Therapeutics Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Design Therapeutics Says Eye Drops for Fuchs Endothelial Corneal Dystrophy 'Well-Tolerated' - marketscreener.com
Design Therapeutics To Initiate Phase 2 Biomarker Trial Of DT-168 In FECD In 2H 2025 - Nasdaq
Design Therapeutics (DSGN) Reveals Positive Phase 1 Trial Results for DT-168 | DSGN Stock News - GuruFocus
Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy - The Manila Times
JPMorgan Chase & Co. Buys 48,528 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor - PR Newswire
Geode Capital Management LLC Purchases 3,090 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Applying computational protein design to therapeutic antibody discoverycurrent state and perspectives - Frontiers
Synthetic Design Lab Emerges with $20M to Advance Next-Generation ADCs - Business Wire
Biotech stocks jump as Makary outlines FDA vision, RBC comments - Baystreet.ca
Design Therapeutics Announces Update on DT-168 Program for Fuchs Endothelial Corneal Dystrophy at Eyecelerator 2025 - Nasdaq
Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025 - The Manila Times
Design Therapeutics Phase 1 Data Shows Promise for Novel FECD Eye Drop Treatment | DSGN Stock News - Stock Titan
Ono Commences Research Collaboration with Jorna Therapeutics to Generate Novel RNA Editing Therapeutics - Business Wire
Forget the Correction: 2 Artificial Intelligence Stocks That Are Still Worth Buying Anyway - The Globe and Mail
April 2025's Promising Penny Stocks - Yahoo Finance
Design Therapeutics names new Chief Medical Officer By Investing.com - Investing.com Canada
Design Therapeutics Names Chris Storgard as Chief Medical Officer - marketscreener.com
Design Therapeutics Inc Stock (DSGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):